SCHEMBL22845327

SCHEMBL22845327

Nc1cnn2c3c(c(=O)n(-c4ccccc4)c12)CCN(C(=O)c1ccc(Cl)c(Cl)c1)C3

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
LMNA P02545 3/20 0.39
P2RX7 Q99572 2/20 0.38
HPGD P15428 1/20 0.38
MTHFD2 P13995 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 2/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 1/20 0.37
PGR P06401 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
PKM P14618 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22845213 0.90 MTHFD2 (0.43) TACR3SMN1; SMN2LMNAP2RX7HPGD
SCHEMBL22845326 0.89 MAPT (0.46) SMN1; SMN2LMNAMEN1KMT2AMAPT
SCHEMBL22845286 0.86 LMNA (0.40) TACR3SMN1; SMN2LMNAP2RX7HPGD
SCHEMBL22845368 0.85 PREP (0.40) SMN1; SMN2LMNAMTHFD2MEN1KMT2A
SCHEMBL22845214 0.84 LMNA (0.37) TACR3SMN1; SMN2LMNAP2RX7HPGD
SCHEMBL22845287 0.84 LMNA (0.37) TACR3SMN1; SMN2LMNAP2RX7HPGD
SCHEMBL22845409 0.84 TSHR (0.40) TACR3SMN1; SMN2LMNAP2RX7HPGD
SCHEMBL22845369 0.84 NPY2R (0.39) SMN1; SMN2LMNAMTHFD2MAPTALDH1A1
SCHEMBL22845202 0.83 LMNA (0.40) TACR3SMN1; SMN2LMNAHPGDMEN1
SCHEMBL22845328 0.82 ALDH1A1 (0.40) SMN1; SMN2LMNAP2RX7HPGDMTHFD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL TACR3 2928/4885SMN1; SMN2 1114/4885LMNA 1680/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL TACR3 2928/4885SMN1; SMN2 1114/4885LMNA 1680/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL TACR3 2928/4885SMN1; SMN2 1114/4885LMNA 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.